About: A HIGH THROUGH-PUT ASSAY FOR CIRCULATING ANTIBODIES DIRECTED AGAINST THE S PROTEIN OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A HIGH THROUGH-PUT ASSAY FOR CIRCULATING ANTIBODIES DIRECTED AGAINST THE S PROTEIN OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	A HIGH THROUGH-PUT ASSAY FOR CIRCULATING ANTIBODIES DIRECTED AGAINST THE S PROTEIN OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
Creator	Krammer, Florian Zolla-Pazner, Susan Kojic, Erna Simon, Viviana Amanat, Fatima Baine, Ian Hioe, Catarina Liu, Sean Bermudez-Gonzalez, Maria Jurczyszak, Denise Klingler, Jéromine Stoever, Jonathan Weiss, Svenja
source	MedRxiv; Medline; PMC
abstract	BACKGROUND. More than one million infections with the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) have been confirmed. While PCR-based assays are used for diagnosis, high through-put serologic methods are needed to detect antibodies for seroserveillance and for identification of seroconversion, potential plasma donors, and the nature of the immune response to this pathogen. METHODS. A Luminex binding assay was used to assess the presence of antibodies in human sera from COVID-19-infected and -uninfected individuals specific for two recombinant proteins of SARS-CoV-2. FINDINGS. Fluorochrome-labeled beads were coated with a recombinant soluble stabilized trimeric SARS-CoV-2 S protein ectodomain or its central portion, the receptor binding domain (RBD). Coated beads were incubated with sera, followed by incubation with biotinylated anti-human total Ig antibodies and phycoerythrin (PE)-labeled streptavidin. Readout using a Luminex analyzer clearly differentiated between sera of the infected and uninfected subjects, delineating a wide range of serum antibody levels in infected subjects. INTERPRETATION. Antibody assays of sera can identify individuals who are infected with SARS-CoV-2 and have seroconverted, as well as subjects who have been infected and recovered. The use of the Luminex binding Ab assay has the advantage that it can be run in approximately 2.5 hours, uses very little antigen, and permits a high through-put of samples/day. FUNDING. NIAID contracts and grants, Department of Veterans Affairs’ grants, the Microbiology Laboratory Clinical Services, Translational Science Hub, and Personalized Virology Initiative, and Department of Medicine of Mount Sinai Health System and Icahn School of Medicine at Mount Sinai.
has issue date	2020-04-17(xsd:dateTime)
bibo:doi	10.1101/2020.04.14.20059501
bibo:pmid	32511609
has license	cc-by-nc-nd
sha1sum (hex)	65edaffab72c14585109aeee9c797c0b2ac24446
schema:url	https://doi.org/10.1101/2020.04.14.20059501
resource representing a document's title	A HIGH THROUGH-PUT ASSAY FOR CIRCULATING ANTIBODIES DIRECTED AGAINST THE S PROTEIN OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
has PubMed Central identifier	PMC7276036
has PubMed identifier	32511609
schema:publication	medRxiv
resource representing a document's body	covid:65edaffab72c14585109aeee9c797c0b2ac24446#body_text
is schema:about of	named entity 'assays' named entity 'infections' named entity 'IDENTIFICATION' named entity 'CONFIRMED' named entity 'VIRUS' named entity 'FOR DIAGNOSIS' named entity 'NEEDED' named entity 'diagnosis' named entity 'pathogen' named entity 'plasma' named entity 'SARS-CoV-2' named entity 'severe acute respiratory syndrome' named entity 'corona virus' named entity 'pathogen' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2' named entity 'ANTIBODIES' named entity 'SARS-CoV-2' named entity 'Phycoerythrin' named entity 'antigen' named entity 'preprint' named entity 'CC-BY-NC-ND 4.0' named entity 'PBS' named entity 'preprint' named entity 'virus' named entity 'serum samples' named entity 'CC-BY-NC-ND 4.0' named entity 'PCR' named entity 'antigen' named entity 'titrations' named entity 'titration' named entity 'amino acids' named entity 'bead' named entity 'Molecular testing' named entity 'peer-reviewed' named entity 'recombinant form' named entity 'recombinant' named entity 'SARS-Cov-2' named entity 'Pathology Laboratory' named entity 'seroconversion' named entity 'peer-reviewed' named entity 'preprint' named entity 'Streptavidin' named entity 'preprint' named entity 'Mount Sinai' named entity 'SARS-CoV-2' named entity 'preprint' named entity 'preprint' named entity 'preprint' named entity 'medRxiv' named entity 'preprint' named entity 'virus' named entity 'RBD' named entity 'BioLegend' named entity 'ThermoFisher' named entity 'preprint' named entity 'RBD' named entity 'seroconverted' named entity 'patient specimens' named entity 'BSA' named entity 'PBS' named entity 'Abcam' named entity 'COVID' named entity 'SARS-CoV' named entity 'preprint' named entity 'antigens' named entity 'mammalian cells' named entity 'peer-reviewed' named entity 'PCR' named entity 'study design'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software